3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
3
Gynecologic
1
Gastrointestinal
1
CNS
1
Conditions
Carcinoma, Hepatocellular
8
Uveal Melanoma
1
Stomach Neoplasms
1
Resectable Hepatocellular Carcinoma
1
Neoplasms
1
Liver Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Carcinoma
1
Advanced Pancreatic Cancer
1
Interventions
Cyclophosphamide
3
pembrolizumab
2
Melphalan
2
utomilumab
1
tislelizumab
1
spartalizumab
1
niraparib
1
montanide ISA 51
1
entinostat
1
binimetinib
1
Toll-Like Receptor 1
1
Rose Bengal
1
Protein Kinase C
1
Nivolumab
1
Interleukin-2
1
Injections
1
Imatinib Mesylate
1
Cryosurgery
1
Crizotinib
1
Blood Specimen Collection
1
Bevacizumab
1
Amplified Fragment Length Polymorphism Analysis
1
ADI PEG20
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uveal Melanoma
×
ADI PEG20
×
Gastrointestinal
×
Clear all
NCT02029690
2020-09-25
TRAP
Polaris Group
Phase 1
Terminated
85 enrolled